Researchers from the RIKEN Research Centre for Allergy and Immunology in Japan report today that they have succeeded for the first time in creating cancer-specific immune system cells called killer T lymphocytes from induced pluripotent stem cells (iPS cells). To create these killer cells, the team first had to reprogram T lymphocytes specialized in killing a certain type of cancer, into iPS cells. The iPS cells then generated fully active, cancer-specific T lymphocytes. These lymphocytes regenerated from iPS cells could potentially serve as cancer therapy in the future.
Science Daily, Dec 27, 2012
Raul Vizcardo, et al, Regeneration of Human Tumor Antigen-Specific T Cells from iPSCs Derived from Mature CD8+ T Cells.
Cell Stem Cell, 2012; 12 (1): 31-36